抗体契约製造市场：依产品类型、原料、最终用户、地区划分

预计2024年全球抗体契约製造市场规模为196.1亿美元，预计2031年将达383亿美元，2024年至2031年复合年增长率为10%。

图：2024 年抗体契约製造市场占有率（%），依地区划分

抗体是免疫系统 B 细胞产生的糖蛋白，用于中和细菌和病毒等病原体。抗体契约製造已成为生物技术和製药公司采用的一种外包策略，用于商业规模开发和生产抗体。抗体开发所需的高研发投资、缺乏内部生产能力以及对核心能力的关注等因素正在推动对合约服务的需求。此外，细胞株工程和精製技术的不断进步使契约製造製造商能够提供大量高品质、稳定的抗体。因此，契约製造已牢固确立为全球公认的经营模式。

市场动态：

全球抗体契约製造市场受到生物製药公司研发费用增加、单株抗体疗法进步、对核心能力的日益关注以及非核心业务外包等因素的推动。然而，严格的监管流程、品质规范、技术转移的潜在风险以及有限的产能等因素给业务的顺利运作带来了挑战。同时，对生技改良药和具有成本效益的抗体的需求不断增长、分子工程工具的进步以及印度和中国等新兴国家生技药品行业的崛起，都带来了巨大的市场机会。

本研究的主要特点

本报告对全球抗体契约製造市场进行了详细分析，包括以2023年为基准年的预测期（2024-2031）的市场规模（十亿美元）和年复合成长率（CAGR，%）。

它还揭示了各个细分市场的潜在商机，并解释了该市场中有吸引力的投资提案的矩阵。

它还提供了有关市场驱动因素、限制因素、机会、新产品发布和核准、市场趋势、区域前景、主要企业采取的竞争策略等的主要考察， FUJIFILM Diosynth Biotechnologies、Rentschler Biopharma SE、Charles River Laboratories、 Samsung Biologics、艾伯维合约製造公司、默克公司、BioNTech SE、安进公司、基因泰克、 Inc.、工业、Celerion、Avid Bioservices, Inc.

该报告的见解使负责人和公司经营团队能够就未来的产品发布、产品升级、市场扩张和行销策略做出明智的决策。

全球抗体契约製造市场报告针对该行业的各个相关人员，如投资者、供应商、产品製造商、经销商、新进业者和财务分析师。

透过用于分析全球抗体契约製造市场的各种策略矩阵，将有助于相关人员做出决策。

目录

第一章 分析目的与前提

• 分析目的
• 先决条件
• 简称

第二章 市场展望

• 报告说明
  • 市场定义和范围
• 执行摘要

第三章市场动态、法规与趋势分析

• 市场动态
• 影响分析
• 主要亮点
• 监管场景
• 产品发布/核准
• PEST分析
• 波特的分析
• 企业合併(M&A) 场景
• 产业动态

第四章全球抗体契约製造市场：依产品类型，2019-2031（十亿美元）

• 单株抗体
• 多株抗体
• 其他的

第五章 全球抗体契约製造市场：依原料分类，2019-2031（十亿美元）

• 哺乳动物细胞
• 微生物系统
• 其他的

第六章 全球抗体契约製造市场：依最终用户划分，2019-2031 年（十亿美元）

• 生物製药公司
• 实验室
• 其他的

第七章 全球抗体契约製造市场：依地区划分，2019-2031（十亿美元）

• 北美洲
• 拉丁美洲
• 欧洲
• 亚太地区
• 中东
• 非洲

第八章 竞争格局

• Lonza Group
• WuXi Biologics
• Catalent, Inc.
• Fujifilm Diosynth Biotechnologies
• Rentschler Biopharma SE
• Charles River Laboratories
• Samsung Biologics
• AbbVie Contract Manufacturing
• Merck KGaA
• BioNTech SE
• Amgen, Inc.
• Genentech, Inc.
• Takeda Pharmaceutical Company
• Celerion
• Avid Bioservices, Inc.

第九章 分析师建议

• 《命运之轮》
• 分析师观点
• Coherent Opportunity Map (COM)

第10章 参考文献与调查方法

• 参考
• 分析方法
• 关于相干市场洞察

The global antibodies contract manufacturing market is estimated to be valued at USD 19.61 Bn in 2024 and is expected to reach USD 38.30 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 10% from 2024 to 2031.

Figure. Antibodies Contract Manufacturing Market Share (%), By Region 2024

Antibodies are glycoproteins produced by B cells of the immune system to neutralize pathogens like bacteria and viruses. Contract manufacturing of antibodies has emerged as an outsourcing strategy adopted by biotech and pharmaceutical companies to develop and produce antibodies on a commercial scale. Factors such as hefty R&D investments required for antibody development, lack of in-house production capabilities, and focus on core competencies have boosted the demand for contract services. Moreover, continued advancements in cell line engineering and purification techniques have enabled contract manufacturers to provide high quality, consistent antibodies in large quantities. This has solidified antibodies contract manufacturing as an established business model worldwide.

Market Dynamics:

The global antibodies contract manufacturing market is driven by factors such as rising R&D expenditure of biopharmaceutical companies, advancement of monoclonal antibody therapeutics, growing focus on core competencies, and outsourcing of non-core activities. However, factors such as stringent regulatory processes and quality specifications, potential risks of technology transfer and capacity constraints pose challenges for smooth operations. On the brighter side, the market sees lucrative opportunities owing to increasing demand for bio-better and cost-effective antibodies, progress in molecular engineering tools, and emergence of developing biologics industry in countries like India and China.

Key Features of the Study:

This report provides in-depth analysis of the global antibodies contract manufacturing market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2024-2031), considering 2023 as the base year

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market

This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players Lonza Group, WuXi Biologics, Catalent, Inc., Fujifilm Diosynth Biotechnologies, Rentschler Biopharma SE, Charles River Laboratories, Samsung Biologics, AbbVie Contract Manufacturing, Merck KGaA, BioNTech SE, Amgen, Inc., Genentech, Inc., Takeda Pharmaceutical Company, Celerion, and Avid Bioservices, Inc.

Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics

The global antibodies contract manufacturing market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global antibodies contract manufacturing market

Market Segmentation

• By Product Type Insights (Revenue, USD Bn, 2019 - 2031)
  • Monoclonal Antibodies
  • Polyclonal Antibodies
  • Others
• By Source Insights (Revenue, USD Bn, 2019 - 2031)
  • Mammalian Cells
  • Microbial Systems
  • Others
• By End User Insights (Revenue, USD Bn, 2019 - 2031)
  • Biopharmaceutical Companies
  • Research Laboratories
  • Others
• Regional Insights (Revenue, USD Bn, 2019 - 2031)
  • North America
  • U.S.
  • Canada
  • Latin America
  • Brazil
  • Argentina
  • Mexico
  • Rest of Latin America
  • Europe
  • Germany
  • U.K.
  • Spain
  • France
  • Italy
  • Russia
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Middle East
  • GCC Countries
  • Israel
  • Rest of Middle East
  • Africa
  • South Africa
  • North Africa
  • Central Africa
• Key Players Insights
  • Lonza Group
  • WuXi Biologics
  • Catalent, Inc.
  • Fujifilm Diosynth Biotechnologies
  • Rentschler Biopharma SE
  • Charles River Laboratories
  • Samsung Biologics
  • AbbVie Contract Manufacturing
  • Merck KGaA
  • BioNTech SE
  • Amgen, Inc.
  • Genentech, Inc.
  • Takeda Pharmaceutical Company
  • Celerion
  • Avid Bioservices, Inc.

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Global Antibodies Contract Manufacturing Market, By Product Type
  • Global Antibodies Contract Manufacturing Market, By Source
  • Global Antibodies Contract Manufacturing Market, By End User
  • Global Antibodies Contract Manufacturing Market, By Region

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Driver
  • Restraint
  • Opportunity
• Impact Analysis
• Key Developments
• Regulatory Scenario
• Product Launches/Approvals
• PEST Analysis
• PORTER's Analysis
• Merger and Acquisition Scenario
• Industry Trends

4. Global Antibodies Contract Manufacturing Market, By Product Type, 2019-2031, (USD Bn)

• Introduction
  • Market Share Analysis, 2024 and 2031 (%)
  • Y-o-Y Growth Analysis, 2020 - 2031
  • Segment Trends
• Monoclonal Antibodies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Polyclonal Antibodies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Others
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

5. Global Antibodies Contract Manufacturing Market, By Source, 2019-2031, (USD Bn)

• Introduction
  • Market Share Analysis, 2024 and 2031 (%)
  • Y-o-Y Growth Analysis, 2020 - 2031
  • Segment Trends
• Mammalian Cells
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Microbial Systems
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Others
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

6. Global Antibodies Contract Manufacturing Market, By End User, 2019-2031, (USD Bn)

• Introduction
  • Market Share Analysis, 2024 and 2031 (%)
  • Y-o-Y Growth Analysis, 2020 - 2031
  • Segment Trends
• Biopharmaceutical Companies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Research Laboratories
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Others
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

7. Global Antibodies Contract Manufacturing Market, By Region, 2019 - 2031, Value (USD Bn)

• Introduction
  • Market Share (%) Analysis, 2024,2027 & 2031, Value (USD Bn)
  • Market Y-o-Y Growth Analysis (%), 2020 - 2031, Value (USD Bn)
  • Regional Trends
• North America
  • Introduction
  • Market Size and Forecast, By Product Type, 2019 - 2031, Value (USD Bn)
  • Market Size and Forecast, By Source, 2019 - 2031, Value (USD Bn)
  • Market Size and Forecast, By End User, 2019 - 2031, Value (USD Bn)
  • Market Size and Forecast, By Country, 2019 - 2031, Value (USD Bn)
    • U.S.
    • Canada
• Latin America
  • Introduction
  • Market Size and Forecast, By Product Type, 2019 - 2031, Value (USD Bn)
  • Market Size and Forecast, By Source, 2019 - 2031, Value (USD Bn)
  • Market Size and Forecast, By End User, 2019 - 2031, Value (USD Bn)
  • Market Size and Forecast, By Country, 2019 - 2031, Value (USD Bn)
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, By Product Type, 2019 - 2031, Value (USD Bn)
  • Market Size and Forecast, By Source, 2019 - 2031, Value (USD Bn)
  • Market Size and Forecast, By End User, 2019 - 2031, Value (USD Bn)
  • Market Size and Forecast, By Country, 2019 - 2031, Value (USD Bn)
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, By Product Type, 2019 - 2031, Value (USD Bn)
  • Market Size and Forecast, By Source, 2019 - 2031, Value (USD Bn)
  • Market Size and Forecast, By End User, 2019 - 2031, Value (USD Bn)
  • Market Size and Forecast, By Country, 2019 - 2031, Value (USD Bn)
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
• Middle East
  • Introduction
  • Market Size and Forecast, By Product Type, 2019 - 2031, Value (USD Bn)
  • Market Size and Forecast, By Source, 2019 - 2031, Value (USD Bn)
  • Market Size and Forecast, By End User, 2019 - 2031, Value (USD Bn)
  • Market Size and Forecast, By Country, 2019 - 2031, Value (USD Bn)
    • GCC Countries
    • Israel
    • Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, By Product Type, 2019 - 2031, Value (USD Bn)
  • Market Size and Forecast, By Source, 2019 - 2031, Value (USD Bn)
  • Market Size and Forecast, By End User, 2019 - 2031, Value (USD Bn)
  • Market Size and Forecast, By Country/Region, 2019 - 2031, Value (USD Bn)
    • South Africa
    • North Africa
    • Central Africa

8. Competitive Landscape

• Lonza Group
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• WuXi Biologics
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Catalent, Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Fujifilm Diosynth Biotechnologies
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Rentschler Biopharma SE
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Charles River Laboratories
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Samsung Biologics
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• AbbVie Contract Manufacturing
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Merck KGaA
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• BioNTech SE
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Amgen, Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Genentech, Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Takeda Pharmaceutical Company
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Celerion
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Avid Bioservices, Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies

9. Analyst Recommendations

• Wheel of Fortune
• Analyst View
• Coherent Opportunity Map

10. References and Research Methodology

• References
• Research Methodology
• About us